Benzinga | Dec 10, 2020 08:33AM EST

VistaGen Announces Korean Intellectual Property Office Decision To Grant PH10 Patent For Treatment Of Depression

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ:VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Korean Intellectual Property Office (KIPO) in the Republic of Korea has issued a Decision to Grant Patent Application No. 10-2015-7020176 related to methods of treating depressive disorder with VistaGen's PH10, an investigational neuroactive nasal spray designed to have rapid-onset therapeutic potential in several neuropsychiatric indications involving depression, initially as potential stand-alone treatment for major depressive disorder (MDD). The patent is not set to expire earlier than 2034.